Astellas Pharma logo
Astellas Pharma
ALPMF | OTC
Chart Builder DCF Calculator
$17.50
+$0.18 (+1.04%)
At close: Nov 16, 2026, 1:57 PM ET
$17.30
-$0.20 (-1.14%)
Pre-market: Nov 16, 2026, 9:32 AM ET

Astellas Pharma Company Profile

Company profile explained

Company Profile

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, encompassing the development, manufacturing, distribution, and commercialization of medicinal products across international markets. Its diverse portfolio features prominent therapies such as XTANDI, an androgen receptor signaling inhibitor for prostate cancer, and XOSPATA, an FLT3 inhibitor targeting relapsed or refractory acute myeloid leukemia in adult patients with a specific FLT3 mutation. Other key offerings include PADCEV, designed for locally advanced or metastatic urothelial cancer, and the Betanis/Myrbetriq/BETMIGA family of beta-3 adrenergic receptor agonists used to alleviate symptoms of overactive bladder, including urgency, frequent urination, and urge incontinence. The company also markets Evrenzo, an oral medication for anemia linked to chronic kidney disease, and the immunosuppressants Prograf and Advagraf/Graceptor/ASTAGRAF, critical for preventing organ rejection post-transplantation. Further contributions to its product range include mirabegron for neurogenic detrusor overactivity in children, Vesicare for general overactive bladder treatment, Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, and the antifungal agent Funguard/MYCAMINE. Astellas is actively engaged in numerous strategic alliances and collaborations to advance its research and development initiatives. These include clinical trial partnerships with Merck & Co., Inc. and CytomX Therapeutics, Inc., as well as an agreement with BANDAI NAMCO Entertainment Inc. for a smartphone-based exercise support application. The company maintains a strategic research alliance with Harvard University, focusing on the co-development of novel therapeutics and technologies. Additionally, it has a research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies utilizing Actinium's Antibody Warhead Enabling technology platform, and an agreement with Zenith Epigenetics Ltd. to assess ZEN-3694. A collaboration agreement is also in place with Cytokinetics, Incorporated. Furthermore, Astellas has a strategic collaboration and licensing deal with Minovia Therapeutics Ltd. aimed at the research, development, and commercialization of cell therapy programs addressing diseases stemming from mitochondrial dysfunction. Established in 1923, Astellas Pharma Inc. has its corporate headquarters situated in Tokyo, Japan.

Key Executives

Name Position
Naoki Okamura President, CEO & Representative Director
Atsushi Kitamura Chief Financial Officer
Katsuyoshi Sugita Executive Vice President, Chief People Officer & Representative Director
Jun Kono Senior Executive Officer & Head of Japan Commercial
Leticia Delgado-Herrera Vice President and Rx+ M&D Head
Nahrin Marino General Counsel and Chief Ethics & Compliance Officer
Nobuaki Tanaka President of Japan Commercial & Senior Corporate Executive
Nobue Yasuda General Manager of Finance & Accounting Department
Nobuko Kato Chief Communications & Investor Relations Officer
Nori Kuwahara Senior Vice President of Planning & Administration
Tatjana Dragovic General Counsel, Chief Ethics & Compliance Officer
Yoshitsugu Shitaka Chief Scientific Officer & Senior Managing Executive Officer
Astellas Pharma
Astellas Pharma logo
Country Japan
IPO Date Apr 26, 2010
Industry Drug Manufacturers - General
Sector Healthcare
Employees 14,099
CEO Naoki Okamura

Contact Details

2-5-1, Nihonbashi-Honcho Tokyo, TY 103-8411 Japan

Stock Details

Ticker Symbol ALPMF
Exchange OTC
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001376684
CUSIP Number n/a
ISIN Number JP3942400007
SIC Code

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.